Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Veda N. Giri; Karen E. Knudsen; William K. Kelly; Wassim Abida; Gerald L. Andriole; Chris H. Bangma; Justin E. Bekelman; Mitchell C. Benson; Amie Blanco; Arthur Burnett; William J. Catalona; Kathleen A. Cooney; Matthew Cooperberg; David E. Crawford; Robert B. Den; Adam P. Dicker; Scott Eggener; Neil Fleshner; Matthew L. Freedman; Freddie C. Hamdy; Jean Hoffman-Censits; Mark D. Hurwitz; Colette Hyatt; William B. Isaacs; Christopher J. Kane; Philip Kantoff; R. Jeffrey Karnes; Lawrence I. Karsh; Eric A. Klein; Daniel W. Lin; Kevin R. Loughlin; Grace Lu-Yao; S. Bruce Malkowicz; Mark J. Mann; James R. Mark; Peter A. McCue; Martin M. Miner; Todd Morgan; Judd W. Moul; Ronald E. Myers; Sarah M. Nielsen; Elias Obeid; Christian P. Pavlovich; Stephen C. Peiper; David F. Penson; Daniel Petrylak; Curtis A. Pettaway; Robert Pilarski; Peter A. Pinto; Wendy Poage; Ganesh V. Raj; Timothy R. Rebbeck; Mark E. Robson; Matt T. Rosenberg; Howard Sandler; Oliver Sartor; Edward Schaeffer; Gordon F. Schwartz; Mark S. Shahin; Neal D. Shore; Brian Shuch; Howard R. Soule; Scott A. Tomlins; Edouard J. Trabulsi; Robert Uzzo; Donald J.Vander Griend; Patrick C. Walsh; Carol J. Weil; Richard Wender; Leonard G. Gomella

doi:10.1200/JCO.2017.74.1173

Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Veda N. Giri, Karen E. Knudsen, William K. Kelly, Wassim Abida, Gerald L. Andriole, Chris H. Bangma, Justin E. Bekelman, Mitchell C. Benson, Amie Blanco, Arthur Burnett, William J. Catalona, Kathleen A. Cooney, Matthew Cooperberg, David E. Crawford, Robert B. Den, Adam P. Dicker, Scott Eggener, Neil Fleshner, Matthew L. Freedman, Freddie C. HamdyJean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, William B. Isaacs, Christopher J. Kane, Philip Kantoff, R. Jeffrey Karnes, Lawrence I. Karsh, Eric A. Klein, Daniel W. Lin, Kevin R. Loughlin, Grace Lu-Yao, S. Bruce Malkowicz, Mark J. Mann, James R. Mark, Peter A. McCue, Martin M. Miner, Todd Morgan, Judd W. Moul, Ronald E. Myers, Sarah M. Nielsen, Elias Obeid, Christian P. Pavlovich, Stephen C. Peiper, David F. Penson, Daniel Petrylak, Curtis A. Pettaway, Robert Pilarski, Peter A. Pinto, Wendy Poage, Ganesh V. Raj, Timothy R. Rebbeck, Mark E. Robson, Matt T. Rosenberg, Howard Sandler, Oliver Sartor, Edward Schaeffer, Gordon F. Schwartz, Mark S. Shahin, Neal D. Shore, Brian Shuch, Howard R. Soule, Scott A. Tomlins, Edouard J. Trabulsi, Robert Uzzo, Donald J.Vander Griend, Patrick C. Walsh, Carol J. Weil, Richard Wender, Leonard G. Gomella^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › peer-review

155 Scopus citations

Abstract

Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods: An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results: Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion: To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

Original language	English (US)
Pages (from-to)	414-424
Number of pages	11
Journal	Journal of Clinical Oncology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1200/JCO.2017.74.1173
State	Published - Feb 1 2018

Funding

Hanjani Institute for Gynecologic Oncology; Abington Hospital-Jefferson Health Atlantic Urology Clinics/Carolina Urologic Research Center Yale University Prostate Cancer Foundation University of Michigan Medical School Jefferson Sidney Kimmel Cancer Center Fox Chase Cancer Center The University of Chicago Johns Hopkins Medical Institutions National Cancer Institute American Cancer Society The University of Chicago Fox Chase Cancer Center Johns Hopkins Medical Institutions Jefferson Sidney Kimmel Cancer Center Vanderbilt University Medical Center Yale University The University of Texas MD Anderson Cancer Center The Ohio State University National Cancer Institute Prostate Conditions Education Council University of Texas Southwestern Medical Center at Dallas Dana Farber Cancer Institute and Harvard TH Chan School of Public Health Memorial Sloan Kettering Cancer Center Mid-Michigan Health Center Cedars-Sinai Medical Center Tulane University Medical School Northwestern University, Feinberg School of Medicine; R.H. Lurie Comprehensive Cancer Center Foundation for Breast and Prostate Health (continued on following page)

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2017.74.1173

Cite this

Giri, V. N., Knudsen, K. E., Kelly, W. K., Abida, W., Andriole, G. L., Bangma, C. H., Bekelman, J. E., Benson, M. C., Blanco, A., Burnett, A., Catalona, W. J., Cooney, K. A., Cooperberg, M., Crawford, D. E., Den, R. B., Dicker, A. P., Eggener, S., Fleshner, N., Freedman, M. L., ... Gomella, L. G. (2018). Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017. Journal of Clinical Oncology, 36(4), 414-424. https://doi.org/10.1200/JCO.2017.74.1173

@article{d64b7d1b2b184e54b468285e6f39d395,

title = "Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017",

abstract = "Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods: An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results: Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion: To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.",

author = "Giri, {Veda N.} and Knudsen, {Karen E.} and Kelly, {William K.} and Wassim Abida and Andriole, {Gerald L.} and Bangma, {Chris H.} and Bekelman, {Justin E.} and Benson, {Mitchell C.} and Amie Blanco and Arthur Burnett and Catalona, {William J.} and Cooney, {Kathleen A.} and Matthew Cooperberg and Crawford, {David E.} and Den, {Robert B.} and Dicker, {Adam P.} and Scott Eggener and Neil Fleshner and Freedman, {Matthew L.} and Hamdy, {Freddie C.} and Jean Hoffman-Censits and Hurwitz, {Mark D.} and Colette Hyatt and Isaacs, {William B.} and Kane, {Christopher J.} and Philip Kantoff and Karnes, {R. Jeffrey} and Karsh, {Lawrence I.} and Klein, {Eric A.} and Lin, {Daniel W.} and Loughlin, {Kevin R.} and Grace Lu-Yao and Malkowicz, {S. Bruce} and Mann, {Mark J.} and Mark, {James R.} and McCue, {Peter A.} and Miner, {Martin M.} and Todd Morgan and Moul, {Judd W.} and Myers, {Ronald E.} and Nielsen, {Sarah M.} and Elias Obeid and Pavlovich, {Christian P.} and Peiper, {Stephen C.} and Penson, {David F.} and Daniel Petrylak and Pettaway, {Curtis A.} and Robert Pilarski and Pinto, {Peter A.} and Wendy Poage and Raj, {Ganesh V.} and Rebbeck, {Timothy R.} and Robson, {Mark E.} and Rosenberg, {Matt T.} and Howard Sandler and Oliver Sartor and Edward Schaeffer and Schwartz, {Gordon F.} and Shahin, {Mark S.} and Shore, {Neal D.} and Brian Shuch and Soule, {Howard R.} and Tomlins, {Scott A.} and Trabulsi, {Edouard J.} and Robert Uzzo and Griend, {Donald J.Vander} and Walsh, {Patrick C.} and Weil, {Carol J.} and Richard Wender and Gomella, {Leonard G.}",

note = "Publisher Copyright: {\textcopyright} 2017 by American Society of Clinical Oncology.",

year = "2018",

month = feb,

day = "1",

doi = "10.1200/JCO.2017.74.1173",

language = "English (US)",

volume = "36",

pages = "414--424",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

Giri, VN, Knudsen, KE, Kelly, WK, Abida, W, Andriole, GL, Bangma, CH, Bekelman, JE, Benson, MC, Blanco, A, Burnett, A, Catalona, WJ, Cooney, KA, Cooperberg, M, Crawford, DE, Den, RB, Dicker, AP, Eggener, S, Fleshner, N, Freedman, ML, Hamdy, FC, Hoffman-Censits, J, Hurwitz, MD, Hyatt, C, Isaacs, WB, Kane, CJ, Kantoff, P, Karnes, RJ, Karsh, LI, Klein, EA, Lin, DW, Loughlin, KR, Lu-Yao, G, Malkowicz, SB, Mann, MJ, Mark, JR, McCue, PA, Miner, MM, Morgan, T, Moul, JW, Myers, RE, Nielsen, SM, Obeid, E, Pavlovich, CP, Peiper, SC, Penson, DF, Petrylak, D, Pettaway, CA, Pilarski, R, Pinto, PA, Poage, W, Raj, GV, Rebbeck, TR, Robson, ME, Rosenberg, MT, Sandler, H, Sartor, O, Schaeffer, E, Schwartz, GF, Shahin, MS, Shore, ND, Shuch, B, Soule, HR, Tomlins, SA, Trabulsi, EJ, Uzzo, R, Griend, DJV, Walsh, PC, Weil, CJ, Wender, R & Gomella, LG 2018, 'Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017', Journal of Clinical Oncology, vol. 36, no. 4, pp. 414-424. https://doi.org/10.1200/JCO.2017.74.1173

TY - JOUR

T1 - Role of genetic testing for inherited prostate cancer risk

T2 - Philadelphia prostate cancer consensus conference 2017

AU - Giri, Veda N.

AU - Knudsen, Karen E.

AU - Kelly, William K.

AU - Abida, Wassim

AU - Andriole, Gerald L.

AU - Bangma, Chris H.

AU - Bekelman, Justin E.

AU - Benson, Mitchell C.

AU - Blanco, Amie

AU - Burnett, Arthur

AU - Catalona, William J.

AU - Cooney, Kathleen A.

AU - Cooperberg, Matthew

AU - Crawford, David E.

AU - Den, Robert B.

AU - Dicker, Adam P.

AU - Eggener, Scott

AU - Fleshner, Neil

AU - Freedman, Matthew L.

AU - Hamdy, Freddie C.

AU - Hoffman-Censits, Jean

AU - Hurwitz, Mark D.

AU - Hyatt, Colette

AU - Isaacs, William B.

AU - Kane, Christopher J.

AU - Kantoff, Philip

AU - Karnes, R. Jeffrey

AU - Karsh, Lawrence I.

AU - Klein, Eric A.

AU - Lin, Daniel W.

AU - Loughlin, Kevin R.

AU - Lu-Yao, Grace

AU - Malkowicz, S. Bruce

AU - Mann, Mark J.

AU - Mark, James R.

AU - McCue, Peter A.

AU - Miner, Martin M.

AU - Morgan, Todd

AU - Moul, Judd W.

AU - Myers, Ronald E.

AU - Nielsen, Sarah M.

AU - Obeid, Elias

AU - Pavlovich, Christian P.

AU - Peiper, Stephen C.

AU - Penson, David F.

AU - Petrylak, Daniel

AU - Pettaway, Curtis A.

AU - Pilarski, Robert

AU - Pinto, Peter A.

AU - Poage, Wendy

AU - Raj, Ganesh V.

AU - Rebbeck, Timothy R.

AU - Robson, Mark E.

AU - Rosenberg, Matt T.

AU - Sandler, Howard

AU - Sartor, Oliver

AU - Schaeffer, Edward

AU - Schwartz, Gordon F.

AU - Shahin, Mark S.

AU - Shore, Neal D.

AU - Shuch, Brian

AU - Soule, Howard R.

AU - Tomlins, Scott A.

AU - Trabulsi, Edouard J.

AU - Uzzo, Robert

AU - Griend, Donald J.Vander

AU - Walsh, Patrick C.

AU - Weil, Carol J.

AU - Wender, Richard

AU - Gomella, Leonard G.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods: An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results: Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion: To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

AB - Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods: An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results: Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion: To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

UR - http://www.scopus.com/inward/record.url?scp=85041184927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041184927&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.74.1173

DO - 10.1200/JCO.2017.74.1173

M3 - Article

C2 - 29236593

AN - SCOPUS:85041184927

SN - 0732-183X

VL - 36

SP - 414

EP - 424

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 4

ER -

Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this